Published on
April 13, 2026
- 13:52 GMT
FDA Clears Path to Clinic Without Additional IND-Enabling Toxicology studies
FDA removes key barrier, accelerating IND and clinical entry for Cethromycin HCl in liver-stage malaria BALTIMORE, MD, UNITED STATES, April 13, 2026 /EINPresswire.com/ -- AliquantumRx Inc. today announced positive regulatory feedback from its Type B pre …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
